Research & Development Bristol-Myers Squibb and Agenus enter a $1.56bn definitive agreement...

Bristol-Myers Squibb and Agenus enter a $1.56bn definitive agreement to support cancer programme

-

An exclusive international license contract of $1.56 billion has been signed between BMS (Bristol Myers Squibb) and Agenus, for AGEN1777, a bispecific antibody (BsAb) plan developed by Agenus, and for other unrevealed plans.

Agenus will receive $200 million from BMS as an upfront payment with the possibility of receiving up to $1.36 billion in regulatory, advancement, and marketing payments, along with the combined double-digit sale payments.

The BMS will be responsible for the production and worldwide commercialization of AGEN1777 and its associated products, as per the agreement.

Agenus will have the opportunity to conduct clinical trials, as well as combination experiments on some of the properties of AGEN1777, and will actively take part in the promotion of the product once it is launched in the United States.

AGEN1777, a crystallizable fragment-enhanced antibody, is now in the final phase of preclinical trials. It has the potential to boost the anti-tumor efficacy by inhibiting key receptors on T- cells and Nk ( Natural Killer) cells.

Debbie Law, Bristol Myers Squibb Tumor Microenvironment Thematic Research Center head said: “AGEN1777’s differentiated mechanism of action provides the potential for potent anti-tumor activity; catalyzing our clinical TIGIT strategy aimed at serving more patients with unmet needs in cancer.
“We look forward to working with Agenus to develop this important therapy as we continue to combat I-O resistance.”

In preclinical tumor studies where Anti-PD-1 ( Anti programmed cell death protein 1) or Anti-TIGIT ( T cell mono-receptors with Immunoglobulins and ITIM domains) non-specific antibodies are ineffective, the AGEN1777 approach has shown significant capability in enhancing anti-tumor activity.

Agenus is planning to submit an IND ( Investigational New Drug application) to the Food and Drug Administration (FDA) of the United States for the development of AGEN1777 by the end of this year.

BMS aims to accelerate the R&D (Research and Development) phase of this Immuno-oncology project for the indication of cancer like NSCLC ( Non-small cell lung cancer).

BMS and Molecular Templates announced a partnership in February to investigate and discover several new innovative medications.

Latest news

Health-Tech Startup Evidation Opens Up Its Symptom-Logging App To Track Migraine Discomfort

California health technology firm Evidation is making its app for logging symptoms more open to track how migraine symptoms....

According to research, Gilead’s long-acting HIV medication is superior to Truvada

Gilead Sciences (GILD.O) announced that in a late-stage trial, its injectable treatment, lenacapavir, was 40.2% more effective in preventing...

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you